Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an idea of how much the field has changed, clinical guidelines on psoriasis ...

A 40-year-old Hispanic man presented for treatment of dermatitis ... and the patient was told to use the foam as necessary and to continue the shampoo. Psoriasis is a chronic, relapsing ...

CAL/BDP foam, which is approved for once-daily ... was approved for the treatment of plaque psoriasis in adults and adolescents in 2022, and in children aged 6 years or up in 2023.

Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...

ZORYVE foam is under review for the treatment of scalp and body psoriasis by the FDA with a PDUFA target action date of May 22, 2025. ZORYVE cream, 0.3%, is indicated for topical treatment of ...

ESK-001, a tyrosine kinase 2 inhibitor, may be a promising new oral treatment for plaque psoriasis. Patients taking ESK-001 twice daily maintained skin clearance up to a year. ORLANDO — Patients ...

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced new data from two posters ...

"My go-to treatment for skin-only psoriasis is the IL-23 inhibitors ... used in combination with systemic therapy. Availability of foam-based formulations has helped to improve convenience ...